CG
SLNO

Cutler Group’s Soleno Therapeutics SLNO Stock Holding History

Cutler Group’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1K Buy
+100
New +$4.52K ﹤0.01% 2105

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cutler Group's SLNO Position: Q3 2022 in Review

Cutler Group sold out of Soleno Therapeutics (SLNO) in Q3 2022, closing a stake of 73 shares.

Cutler Group first reported a position in SLNO in Q2 2020 and held it in 9 quarters. The position peaked at $2K in Q4 2020. 22 funds tracked by Wall St. Rank hold SLNO as of Q3 2022.

  • Cutler Group reported no remaining Soleno Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 73 Soleno Therapeutics shares in Q3 2022.
  • Cutler Group first reported a position in Soleno Therapeutics in Q2 2020 and held it in 9 quarters.
  • Cutler Group's Soleno Therapeutics position peaked at $2K in Q4 2020.
  • 22 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.